局部应用咪喹莫特与原位外阴黑色素瘤：一种有前景的治疗方法？
Topical imiquimod and in situ vulvar melanoma: A promising therapy?
作者信息
Pepe Francesca, Silvestri Flavia, Preti Eleonora Petra, Iacobone Anna Daniela, Radici Gianluigi, Vaccari Sabina, Queirolo Paola, Tosti Giulio
机构信息
Dermato-Oncology Unit, European Institute of Oncology IRCCS, Milan, Italy.
Preventive Gynecology Unit, European Institute of Oncology IRCCS, Milan, Italy.
出版信息
Int J Gynaecol Obstet. 2025 Aug;170(2):608-613. doi: 10.1002/ijgo.70087. Epub 2025 Apr 3.
OBJECTIVES
Vulvar melanoma is a rare type of cancer that affects mainly postmenopausal women. There are no established protocols for the treatment of vulvar melanoma. From data extrapolated from the literature on cutaneous melanoma, surgical excision remains the best option for the resectable disease. Imiquimod, a topical immunomodulator, has been used in selected cases of in situ vulvar melanoma.
METHODS AND RESULTS
We reported two cases of in situ vulvar melanoma treated with topical imiquimod 5%, either as first-line therapy or adjuvant treatment, that showed a complete clinical response to topical treatment.
CONCLUSION
Imiquimod's beneficial and adverse effects in in situ vulvar melanoma treatment are examined.
目的
外阴黑色素瘤是一种罕见的癌症类型，主要影响绝经后女性。目前尚无既定的外阴黑色素瘤治疗方案。根据从皮肤黑色素瘤文献中推断的数据，手术切除仍然是可切除疾病的最佳选择。咪喹莫特是一种局部免疫调节剂，已用于部分原位外阴黑色素瘤病例。
方法与结果
我们报告了2例原位外阴黑色素瘤病例，使用5%的局部咪喹莫特进行治疗，无论是作为一线治疗还是辅助治疗，均显示出对局部治疗有完全的临床反应。
结论
研究了咪喹莫特在原位外阴黑色素瘤治疗中的有益和不良反应。
Zotero 插件